Advertisement

Clinical Drug Investigation

, Volume 39, Issue 1, pp 1–13 | Cite as

Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials

  • Shijie Zhao
  • Zhaoshuang Zhong
  • Guoxian Qi
  • Liye Shi
  • Wen TianEmail author
Systematic Review
  • 65 Downloads

Abstract

Background and Objective

The results of studies on cilostazol-based triple antiplatelet therapy (TAT) after drug-eluting stent (DES) implantation were inconsistent. To assess the effects of TAT compared with dual antiplatelet therapy (DAT) after DES/second-generation DES implantation, we performed a meta-analysis of randomized controlled trials (RCTs).

Methods

All relevant studies evaluated were identified by searching the PubMed, EMBASE, Cochrane Library, and ISI Web of Science databases without time and language limitation. Subgroup analyses were performed to evaluate the efficacy and safety of TAT after second-generation DES implantation.

Results

Eleven RCTs involving a total of 4684 patients were included. The meta-analysis showed TAT was associated with significant beneficial effects on angiographic findings of in-stent restenosis [risk ratio (RR) 0.645, 95% confidence interval (CI) 0.470–0.885; P = 0.007], in-segment restenosis (RR 0.606, 95% CI 0.450–0.817; P = 0.001), in-stent late loss (RR – 0.095, 95% CI − 0.136 to − 0.054; P < 0.0001), in-segment late loss (RR − 0.100, 95% CI − 0.139 to − 0.061; P < 0.0001), target lesion revascularization (TLR) (RR 0.570, 95% CI 0.430–0.755; P < 0.0001), and target vessel revascularization (TVR) (RR 0.523, 95% CI 0.380–0.719; P < 0.0001). No significant difference was found in outcomes of all-cause death, cardiac death, definite/probable stent thrombosis (ST), non-fatal myocardial infarction (MI), overall bleeding, and major bleeding between the two groups, as well as some minor adverse effects including palpitations, thrombocytopenia, neutropenia, and hepatic dysfunction. However, the incidence rate of rash, gastrointestinal disorders, and headache was significantly higher in TAT. The second-generation DES subgroup showed similar results, except for the indicators of all-cause death (RR 2.161, 95% CI 1.007–4.635; P = 0.048) and hepatic dysfunction (RR 0.176, 95% CI 0.031–0.995; P = 0.049).

Conclusions

Compared with DAT, cilostazol-based TAT can significantly improve the angiographic findings of in-stent and in-segment late loss, in-stent and in-segment restenosis, TLR, and TVR after DES/second-generation DES implantation. However, no benefits were observed in outcomes of all-cause death, cardiac death, ST, and MI.

Notes

Compliance with Ethical Standards

Conflict of interest

Shijie Zhao, Zhaoshuang Zhong, Guoxian Qi, Liye Shi and Wen Tian, declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References:

  1. 1.
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–23.CrossRefGoogle Scholar
  2. 2.
    Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008;42(4):550–7.CrossRefGoogle Scholar
  3. 3.
    Steinhubl SR, Berger PB, Mann JR, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–20.CrossRefGoogle Scholar
  4. 4.
    Grove EL, Wurtz M, Thomas MR, Kristensen SD. Antiplatelet therapy in acute coronary syndromes. Expert Opin Pharmacother. 2015;16(14):2133–47.CrossRefGoogle Scholar
  5. 5.
    Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–907.CrossRefGoogle Scholar
  6. 6.
    Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol. 1999;34(4):497–504.CrossRefGoogle Scholar
  7. 7.
    Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29(18):2202–11.CrossRefGoogle Scholar
  8. 8.
    Kim MJ, Park KG, Lee KM, Kim HS, Kim SY, Kim CS, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension. 2005;45(4):552–6.CrossRefGoogle Scholar
  9. 9.
    Yoo AR, Koh SH, Cho GW, Kim SH. Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway. J Atheroscler Thromb. 2010;17(10):1009–18.CrossRefGoogle Scholar
  10. 10.
    Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. Circ J. 2007;71(11):1685–90.CrossRefGoogle Scholar
  11. 11.
    Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769–76.CrossRefGoogle Scholar
  12. 12.
    Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39(2):183–93.CrossRefGoogle Scholar
  13. 13.
    Song PS, Song YB, Yang JH, Hahn JY, Choi SH, Choi JH, et al. Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry. Heart Vessels. 2015;30(4):458–68.CrossRefGoogle Scholar
  14. 14.
    Lee HJ, Yu CW, Hwang HK, Choi RK, Park JS, Li H, et al. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. Coron Artery Dis. 2013;24(7):542–8.CrossRefGoogle Scholar
  15. 15.
    Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, et al. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol. 2009;68(1):4–13.CrossRefGoogle Scholar
  16. 16.
    Chen Y, Zhang Y, Tang Y, Huang X, Xie Y. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin. 2014;30(1):37–49.CrossRefGoogle Scholar
  17. 17.
    Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;167(5):2250–8.CrossRefGoogle Scholar
  18. 18.
    Zou Y, Hu C, Ye W, Fan L, Xu L, Zhang A. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: a meta-analysis of randomized controlled trials. Thromb Res. 2015;136(5):870–7.CrossRefGoogle Scholar
  19. 19.
    Suh JW, Lee SP, Park K, Kang HJ, Koo BK, Cho YS, et al. The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial. Int Heart J. 2017;58(6):853–60.CrossRefGoogle Scholar
  20. 20.
    Zuliani MM, Mangione JA, Costa JJ, Costa R, Piva EML, Staico R, et al. Randomized angiographic and intravascular ultrasound comparison of dual-antiplatelet therapy vs triple-antiplatelet therapy to reduce neointimal tissue proliferation in diabetic patients. J Invasive Cardiol. 2017;29(3):76–81.Google Scholar
  21. 21.
    Lee CH, Lee J, Park G, Lee S, Kim H, Choi YJ, et al. Comparison of 1-year outcomes of triple (aspirin + clopidogrel + cilostazol) versus dual antiplatelet therapy (aspirin + clopidogrel + placebo) after implantation of second-generation drug-eluting stents into one or more coronary arteries: from the DECREASE-PCI trial. Am J Cardiol. 2018;121(4):423–9.  https://doi.org/10.1016/j.amjcard.2017.11.005.CrossRefGoogle Scholar
  22. 22.
    Zheng XT, Chen KY, Liu T, Xu LX, Che JJ, Rha SW, et al. Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2016;43(1):29–33.CrossRefGoogle Scholar
  23. 23.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64.CrossRefGoogle Scholar
  24. 24.
    Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006. Circulation. 2007;115(17):2352–7.CrossRefGoogle Scholar
  25. 25.
    Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232–6.CrossRefGoogle Scholar
  26. 26.
    Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://handbook.cochrane.org. Accessed 17 Dec 2017.
  27. 27.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRefGoogle Scholar
  28. 28.
    Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011;57(3):280–9.CrossRefGoogle Scholar
  29. 29.
    Lee S, Chun K, Park S, Kim H, Kim Y, Yun S, et al. Comparison of Triple Antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG trials). Am J Cardiol. 2010;105(2):168–73.CrossRefGoogle Scholar
  30. 30.
    Youn YJ, Lee JW, Ahn SG, Lee SH, Choi H, Yu CW, et al. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J. 2014;167(2):241–8.CrossRefGoogle Scholar
  31. 31.
    Gao W, Zhang Q, Ge H, Guo Y, Zhou Z. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology. 2013;64(7):554–8.CrossRefGoogle Scholar
  32. 32.
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 2011;57(11):1264–70.CrossRefGoogle Scholar
  33. 33.
    Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels. 2011;26(5):502–10.CrossRefGoogle Scholar
  34. 34.
    Sung Kum D, Kim M, Hoan Paik J, Han J, Kim K, Ho Park T, et al. Clinical effects of additional cilostazol administration after drug-eluting stent insertion. Korean Circ J. 2009;39:21–5.CrossRefGoogle Scholar
  35. 35.
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol. 2008;51(12):1181–7.CrossRefGoogle Scholar
  36. 36.
    Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100(7):1103–8.CrossRefGoogle Scholar
  37. 37.
    Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198–206.CrossRefGoogle Scholar
  38. 38.
    Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–80.CrossRefGoogle Scholar
  39. 39.
    Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667–78.CrossRefGoogle Scholar
  40. 40.
    Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009–19.CrossRefGoogle Scholar
  41. 41.
    Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733–9.CrossRefGoogle Scholar
  42. 42.
    Chen J, Meng H, Xu L, Liu J, Kong D, Chen P, et al. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis. 2015;39(1):23–34.CrossRefGoogle Scholar
  43. 43.
    Fan ZG, Ding GB, Li XB, Gao XF, Gao YL, Tian NL. The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients. Drug Des Devel Ther. 2016;10:3435–48.CrossRefGoogle Scholar
  44. 44.
    Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA. 2006;103(29):11069–74.CrossRefGoogle Scholar
  45. 45.
    Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl. 2005;6(4):41–6.CrossRefGoogle Scholar
  46. 46.
    Rogers KC, Faircloth JM, Finks SW. Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother. 2012;46(6):839–50.CrossRefGoogle Scholar
  47. 47.
    Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia. 2001;44(8):1034–42.CrossRefGoogle Scholar
  48. 48.
    Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004;44(7):1408–14.CrossRefGoogle Scholar
  49. 49.
    Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol. 2012;59(15):1337–49.CrossRefGoogle Scholar
  50. 50.
    Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127(23):2307–15.CrossRefGoogle Scholar
  51. 51.
    Zen K, Takahara M, Iida O, Soga Y, Kawasaki D, Nanto S, et al. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. J Vasc Surg. 2017;65(3):720–5.CrossRefGoogle Scholar
  52. 52.
    Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109(11):1366–70.CrossRefGoogle Scholar
  53. 53.
    Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, et al. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol. 2007;100(4):610–4.CrossRefGoogle Scholar
  54. 54.
    Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv. 2010;3(1):17–26.CrossRefGoogle Scholar
  55. 55.
    Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014;1(1):e68.CrossRefGoogle Scholar
  56. 56.
    Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100–9.CrossRefGoogle Scholar
  57. 57.
    Wang P, Zhou S, Zhou R, Liu G, Tang P, He J, et al. The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. Clin Cardiol. 2012;35(10):598–604.CrossRefGoogle Scholar
  58. 58.
    D’Ascenzo F, Chieffo A, Cerrato E, Ugo F, Pavani M, Kawamoto H, et al. Incidence and management of restenosis after treatment of unprotected left main disease with second-generation drug-eluting stents (from Failure in Left Main Study With 2nd Generation Stents-Cardiogroup III Study). Am J Cardiol. 2017;119(7):978–82.CrossRefGoogle Scholar
  59. 59.
    Kajiya T, Yamaguchi H, Takaoka J, Fukunaga K, Arima R, Miyamura A, et al. In-stent restenosis assessed by frequency-domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents. Singapore Med J. 2018. https://doi.org/10.11622/smedj.2018038.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Geriatric Cardiology, First Affiliated HospitalChina Medical UniversityShenyangChina
  2. 2.Department of Respiratory, Central HospitalShenyang Medical CollegeShenyangChina

Personalised recommendations